NeuroSense Therapeutics

NeuroSense Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted innovative therapies for neurodegenerative diseases. To date, the company has initiated a breakthrough treatment for ALS, which is expected to halt or significantly delay disease progression, as well as the advancement of Alzheimer's and Parkinson's diseases. NeuroSense is currently preparing for a Phase 2b/3 clinical trial using PrimeC in ALS patients. The company has also begun exploring other potential indications for the drug, including Alzheimer's disease and Parkinson's disease. Additionally, research is being conducted on the mechanisms of action and related biomarkers for these conditions.